PCMC
RNAM

Planning Capital Management Corporation’s Avidity Biosciences RNAM Stock Holding History

Planning Capital Management Corporation’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$689 Buy
15
+3
+25% +$130 ﹤0.01% 653
2024
Q2 		$491 Buy
+12
New +$344 ﹤0.01% 624

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Planning Capital Management Corporation's RNAM Position: Q3 2024 in Review

Planning Capital Management Corporation increased its Avidity Biosciences (RNAM) stake by 25% in Q3 2024, buying an estimated $130 and bringing the position to 15 shares worth $689. The position accounts for ﹤0.01% of the portfolio, ranked #653.

Planning Capital Management Corporation first reported a position in RNAM in Q2 2024 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold RNAM as of Q3 2024.

  • Planning Capital Management Corporation held 15 shares of Avidity Biosciences worth $689 as of Q3 2024.
  • Planning Capital Management Corporation bought 3 Avidity Biosciences shares in Q3 2024, an estimated $130.
  • Avidity Biosciences made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #653 holding.
  • Planning Capital Management Corporation first reported a position in Avidity Biosciences in Q2 2024 and has held it in 2 quarters since.
  • 245 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.